Like millions of other people now using GLP-1 medicines, Samantha knew what physical changes to expect from the treatment
Studies show explosive growth in GLP-1 utilization: In 2023, U.S
A 2025 meta-analysis in PMC (covering 36,754 tirzepatide and 106,057 semaglutide participants across multiple studies) confirmed tirzepatides advantage, finding an average 4.23 percentage points greater weight loss with tirzepatide an effect that was both dose- and duration-dependent
However, individual factorsincluding treatment response, side effects, cost, and personal goalsinfluence how long you'll take these medications
Clinical associations and potential cellular mechanisms linking G6PD deficiency and atherosclerotic cardiovascular disease